Xenon Pharmaceuticals Profit Margin 2012-2022 | XENE
Current and historical gross margin, operating margin and net profit margin for Xenon Pharmaceuticals (XENE) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Xenon Pharmaceuticals net profit margin as of September 30, 2022 is -862.06%.
| Xenon Pharmaceuticals Annual Profit Margins |
| Xenon Pharmaceuticals Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.377B |
$0.018B |
|
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|
